COMING SOON: ReSPECT-LM at SABCS 2024

Exciting News: ReSPECT-LM Leptomeningeal Metastases Clinical Trial to be Showcased at SABCS 2024!

Mark your calendars! Plus Therapeutics is thrilled to present groundbreaking data from our ReSPECT-LM Phase 1 clinical trial at the 2024 San Antonio Breast Cancer Symposium (SABCS). Our innovative study focuses on Rhenium (186Re) Obisbemeda, an emerging treatment for leptomeningeal metastases (LM) in breast cancer patients.

Key Highlights:

• ReSPECT-LM Clinical Trial Data: Phase 1 results of Rhenium (186Re) Obisbemeda for treating leptomeningeal metastases in breast cancer patients.
• Exhibitor Booth at SABCS 2024: Visit us at our booth to learn more about the trial and discuss potential collaborations.

For more details, check out our latest press release:
Press Release – Plus Therapeutics

To schedule a meeting with our team at SABCS 2024, please contact us at:
📧 info@plustherapeutics.com

About ReSPECT-LM

Learn more about our ReSPECT-LM trial, a cutting-edge approach to treating leptomeningeal metastases in breast cancer patients. Explore the trial details here:
ReSPECT-LM Clinical Trial Information

Hashtags to Follow:

#SABCS2024 #LeptomeningealMetastases #BreastCancerResearch #ClinicalTrials #CancerTreatment #RheniumObisbemeda #OncologyResearch #CancerInnovations #PlusTherapeutics #ReSPECTLM #BreastCancerAwareness #MetastaticBreastCancer #PrecisionMedicine